NM108

NM108 is an investigational **botanical drug** being developed by Notitia Biologics as a gastrointestinal microbiome modulator. The product is described as a botanical-based fixed-combination or nutrient formula designed to promote growth of Foundation Guild bacteria in the gut microbiome, including support of existing or replenished Foundation Guild populations, with the goal of restoring microbiome balance in diseases associated with dysbiosis. Public sources indicate the program is in **Phase 2** development and has been made available through expanded access. Clinical development has included COVID-19, especially in patients with type 2 diabetes or prediabetes, and additional Phase 2 study activity has been reported in chemotherapy-induced diarrhea associated with irinotecan treatment in metastatic colon cancer; the company pipeline also lists the asset broadly in Phase 2 without specifying all indications.

Other names

Nutritional MedicineNM108NM-108NM 108